---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031466"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:41:18.077251+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026

## Summary
- Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.
- Bir is a seasoned biopharma executive with prior roles at Reata, Geron, Soleno, and Pharmacyclics.
- Company plans to initiate first clinical study for simufilam in TSC-related epilepsy in first half of 2026.
- Bir eligible for standard non-employee director compensation; no material interests or arrangements disclosed.

## SEC filing metadata
- accession: 0001437749-25-031466
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/0001437749-25-031466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/sava20251020_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031466
- JSON: https://secwatch.observer/filing/0001437749-25-031466.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.